SCHEMBL22686000

SCHEMBL22686000

O=C1OCCN1c1ccc2[nH]nc(-c3cccc(-c4ccccc4)c3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 1/20 0.46
TNKS O95271 1/20 0.45
MKNK1 Q9BUB5 1/20 0.44
PIM1 P11309 5/20 0.44
AXL P30530 1/20 0.44
FGFR1 P11362 1/20 0.41
FGFR2 P21802 1/20 0.41
JAK2 O60674 1/20 0.41
FAAH O00519 1/20 0.41
NAAA Q02083 1/20 0.41
DCLK1 O15075 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
CHEK2 O96017 1/20 0.40
CSF1R P07333 1/20 0.40
FER P16591 1/20 0.40
CDK2 P24941 1/20 0.40
MARK3 P27448 1/20 0.40
FLT4 P35916 1/20 0.40
FLT3 P36888 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22685979 0.93 TNKS (0.49) TTKTNKSMKNK1PIM1AXL
SCHEMBL22685937 0.93 TNKS (0.48) TTKTNKSMKNK1PIM1AXL
SCHEMBL22685994 0.88 JAK2 (0.45) TNKSPIM1JAK2CCNCCDK8
SCHEMBL22685983 0.86 TNKS (0.47) TNKSPIM1FGFR1FGFR2CDK2
SCHEMBL22685957 0.84 MAP2K4 (0.54) TTKPIM1AXLCLK2DYRK1A
SCHEMBL22685984 0.84 MKNK1 (0.45) TNKSMKNK1PIM1FGFR1FGFR2
SCHEMBL22708143 0.83 PIM1 (0.45) TNKSPIM1FGFR1FGFR2CDK2
SCHEMBL22686003 0.82 IDH1 (0.43) TNKSPIM1FGFR1FGFR2CCNC
SCHEMBL22686016 0.81 CCNC (0.43) TNKSPIM1FGFR1FGFR2CCNC
SCHEMBL22685936 0.80 MAPKAPK2 (0.43) TNKSPIM1FGFR1FGFR2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11396505-B2 Inhibitors of CaMKK2 and uses of same NEW YORK UNIVERSITY (US) 2022-07-26 US disclosed
US-11396505-B2 Inhibitors of CaMKK2 and uses of same NEW YORK UNIVERSITY (US) 2022-07-26 US disclosed
US-20200369656-A1 INHIBITORS OF CAMKK2 AND USES OF SAME NEW YORK UNIVERSITY 2020-11-26 US disclosed
US-20200369656-A1 INHIBITORS OF CAMKK2 AND USES OF SAME NEW YORK UNIVERSITY 2020-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11396505-B2 Inhibitors of CaMKK2 and uses of same CAMKK2, CAMKK1, CAMK1 TTK 85/4885TNKS 165/4885MKNK1 141/4885
US-20200369656-A1 INHIBITORS OF CAMKK2 AND USES OF SAME CAMKK2, CAMKK1, CAMK1 TTK 85/4885TNKS 165/4885MKNK1 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.